Holly Phillips. The extremely cold winter, she explained on CBS TODAY, is assisting packing a particular allergy punch this season because plants’ growth is not staggered. What usually happens is spring brings our tree pollen. Summer season brings our grass pollen and in the fall we see ragweed after that, she stated. Because our spring was therefore delayed this year, many things are blooming up all at one time. What should have bloomed over a course of a full month is now popping up altogether, so we’re seeing actually, high pollen levels really.Angiolillo, M.D., Ph.D., Richard C. Becker, M.D., Derek P. Chew, M.B., B.S., M.P.H., William J. French, M.D., Franz Leisch, M.D., Keyur H. Parikh, M.D., Simona Skerjanec, Pharm.D., and Deepak L. Bhatt, M.D., M.P.H.: Platelet Inhibition with Cangrelor in Individuals Undergoing PCI Percutaneous coronary intervention may be complicated by adverse cardiac events including death, myocardial infarction, a dependence on urgent revascularization, and acute, subacute, or past due stent thrombosis, of whether bare-metal or drug-eluting stents are used regardless. 1-3 As a result, antithrombotic therapy can be an important adjunct to PCI.4 Clinical practice recommendations recommend treatment with antiplatelet agents, including clopidogrel, after and during PCI, even though optimal timing, loading dosage, and duration of therapy haven’t been definitively established by randomized clinical trials.5,6 Current guidelines suggest an oral loading dose of 300 to 600 mg of clopidogrel accompanied by 75 mg daily.11,12 Ticagrelor was superior to clopidogrel in patients with acute coronary syndromes, and prasugrel was superior to clopidogrel in individuals with acute coronary syndromes who have been undergoing PCI.13,14 Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is definitely in a class of intravenous blockers of the ADP receptor P2Y12 that might have a role in the treatment of patients who require fast, predictable, and profound but reversible platelet inhibition.15 A direct-acting, selective, and specific P2Y12 inhibitor, cangrelor is metabolized through dephosphorylation pathways and has a plasma half-life of 3 to 6 minutes.